Trial results

Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes

NCT07797036 on ClinicalTrials.gov · last registry update 2026-09-01

An unusually large phase 2/phase 3: 226 participants, more than double the 60 typical for the stage. Due to report 1 September 2030, alongside 4 other tracked readouts that quarter. Primary outcome, as filed: Metabolic Syndrome. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for metabolic syndrome — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

NOT_YET_RECRUITING

Phase

P2/P3

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

University of Massachusetts, Worcester

Sponsor type

Other

Enrollment

226

Started

2027-09-01

Primary completion

2030-09-01 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Metabolic Syndrome

Conditions studied

Gestational Diabetes Mellitus (GDM) · Metabolic Syndrome

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.